Literature DB >> 20590576

Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex.

W-Sv Ho1, S Patel, J R Thompson, C J Roberts, K L Stuhr, C J Hillard.   

Abstract

BACKGROUND AND
PURPOSE: In vitro studies demonstrate that cannabinoid CB(1) receptors subserve activity-dependent suppression of inhibition in the neocortex. To examine this mechanism in vivo, we assessed the effects of local changes in CB(1) receptor activity on somatosensory cortex neuronal activation by whisker movement in rats. EXPERIMENTAL APPROACH: Laser Doppler flowmetry and c-Fos immunohistochemistry were used to measure changes in local blood flow and neuronal activation, respectively. All drugs were applied directly to the cranium above the whisker barrel fields of the primary somatosensory cortex. KEY
RESULTS: The CB(1) receptor agonist WIN55212-2 potentiated the hyperaemia induced by whisker movement and this potentiation was occluded by bicuculline. The CB(1) receptor antagonists, rimonabant and AM251, inhibited hyperaemic responses to whisker movement; indicating that activation of endogenous CB(1) receptors increased during whisker movement. Whisker movement-induced expression of c-Fos protein in neurons of the whisker barrel cortex was inhibited by rimonabant. Movement of the whiskers increased the 2-arachidonoylglycerol content in the contralateral, compared to the ipsilateral, sensory cortex. CONCLUSIONS AND IMPLICATIONS: These results support the hypothesis that endocannabinoid signalling is recruited during physiologically relevant activation of the sensory cortex. These data support the hypothesis that the primary effect of CB(1) receptor activation within the activated whisker barrel cortex is to inhibit GABA release, resulting in disinhibition of neuronal activation. These studies provide physiological data involving endocannabinoid signalling in activity-dependent regulation of neuronal activation and provide a mechanistic basis for the effects of cannabis use on sensory processing in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590576      PMCID: PMC2931572          DOI: 10.1111/j.1476-5381.2010.00772.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells.

Authors:  A C Kreitzer; W G Regehr
Journal:  Neuron       Date:  2001-03       Impact factor: 17.173

3.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

4.  Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors.

Authors:  M Nakazi; U Bauer; T Nickel; M Kathmann; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-01       Impact factor: 3.000

Review 5.  Does glutamate image your thoughts?

Authors:  Gilles Bonvento; Nicola Sibson; Luc Pellerin
Journal:  Trends Neurosci       Date:  2002-07       Impact factor: 13.837

6.  Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.

Authors:  J A Wagner; Z Járai; S Bátkai; G Kunos
Journal:  Eur J Pharmacol       Date:  2001-07-06       Impact factor: 4.432

7.  Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain.

Authors:  G Marsicano; B Lutz
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

8.  The CB1 receptor antagonist SR141716 enhances stimulus-induced activation of the primary somatosensory cortex of the rat.

Authors:  Sachin Patel; Ronald Gerrits; Shanmugam Muthian; Andrew S Greene; Cecilia J Hillard
Journal:  Neurosci Lett       Date:  2002-12-25       Impact factor: 3.046

9.  Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus.

Authors:  A F Hoffman; C R Lupica
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

10.  Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex.

Authors:  Joseph Trettel; Eric S Levine
Journal:  J Neurophysiol       Date:  2002-07       Impact factor: 2.714

View more
  4 in total

1.  Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.

Authors:  R J Newsom; C Osterlund; C V Masini; H E Day; R L Spencer; S Campeau
Journal:  Neuroscience       Date:  2011-11-28       Impact factor: 3.590

Review 2.  Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.

Authors:  Shana M Augustin; David M Lovinger
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

3.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Authors:  Isabella Canazza; Andrea Ossato; Claudio Trapella; Anna Fantinati; Maria Antonietta De Luca; Giulia Margiani; Fabrizio Vincenzi; Claudia Rimondo; Fabiana Di Rosa; Adolfo Gregori; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

4.  Remote CB1 receptor antagonist administration reveals multiple sites of tonic and phasic endocannabinoid neuroendocrine regulation.

Authors:  R J Newsom; R J Garcia; J Stafford; C Osterlund; C E O'Neill; H E W Day; S Campeau
Journal:  Psychoneuroendocrinology       Date:  2019-12-19       Impact factor: 4.905

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.